Breaking News

Tesco Falls as Much as 11.8% After Saying Profit Overstated
Tweet TWEET

Federal Appellate Court Rules in Favor of Mylan in Patent Infringement Litigation Relating to Sunovion's Brovana® Product

    Federal Appellate Court Rules in Favor of Mylan in Patent Infringement
              Litigation Relating to Sunovion's Brovana® Product

PR Newswire

PITTSBURGH, May 21, 2013

PITTSBURGH, May 21, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
announced that the Court of Appeals for the Federal Circuit has ruled in favor
of Mylan Specialty L.P., f/k/a Dey Pharma, L.P. and has reversed the District
Court's decision invalidating five of Mylan's patents related to Perforomist®.
The Court's reversal of the summary judgment decision reinstates Mylan
Specialty's patents as valid and enforceable. Mylan previously announced a
settlement agreement with Sunovion resolving the litigation relating to
Sunovion's Brovana® product,pending the outcome of the Federal Circuit
appeal.

Mylan CEO Heather Bresch commented, "We are pleased with the Court's decision
as it confirms our original belief in the strength and validity of the
intellectual property protecting Perforomist®, as well as our combination
product for the treatment of Chronic Obstructive Pulmonary Disease (COPD),
currently in development. We believe this decision by the Court only further
supports the strength of our Specialty franchise."

This press release includes statements that constitute "forward-looking
statements," including with regard to the settlement of the litigation. These
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Because such statements inherently
involve risks and uncertainties, actual future results may differ materially
from those expressed or implied by such forward-looking statements. Factors
that could cause or contribute to such differences include, but are not
limited to: any legal or regulatory challenges to the settlement; strategies
by competitors or other third parties to delay or prevent product sales; risks
inherent in legal and regulatory processes; and the other risks detailed in
the company's periodic filings with the Securities and Exchange Commission.
The company undertakes no obligation to update these statements for revisions
or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of approximately 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com

SOURCE Mylan Inc.

Website: http://www.mylan.com
Contact: Nina Devlin (Media), 724.514.1968 or Kris King (Investors),
724.514.1813
 
Press spacebar to pause and continue. Press esc to stop.